009 Piero.p65

نویسندگان

  • Fabio Del Piero
  • Fabio Del Piero
چکیده

## , $ ( & $ ' ( $ % & ' '' . & ' & ( & ' ( & ' % ( % % ' $' $ ( / % ( % 0 ' & % & % $ $ ' $ % ' % ( % $ '& 1 $ % '& ( $ '& / $ $ $ ' & $ 0 ' $ .$ $ $ & / $ $ & ' ' ( $ ' ) ( ' $ ( ( ( $ ' $ & . ( ) & & ( & & 1 % % ' . $ 2 ' $ '& $ $ & ) ' ' % & ' % & % ' ( % ' % ( % % 2 % % % & 3 ' % % % ' $% % % ' % % & $% 1 % % % % % ' 4 ( 1 . & $% " ) ' $% & % 1 ' ( '& ' &$ ' % $ % ' & & ' 5 ' & ' ! & ' . & & ' 1 ' -

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

[Effects of cernitin pollen extract (CN-009) on the isolated bladder smooth muscles and the intravesical pressure].

Cernitin pollen extract (CN-009), extract from several pollen species, has been used for urinary dysfunction. As its mode of action has not been clarified, we investigated the action of CN-009 on the isolated bladder smooth muscles of rats, guinea pigs and cats and the intravesical pressure in female rats. CN-009 contracted isolated detrusor muscles of rats, guinea pigs and cats in a concentrat...

متن کامل

Cancer Therapy: Clinical Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

Purpose: MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen overexpressed in pancreatic cancer, ovarian cancer, mesothelioma, and other malignancies. We conducted a phase I clinical trial of MORAb-009 in patients with advanced mesothelin-expressing cancers to determine its safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). M...

متن کامل

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

PURPOSE MORAb-009 is a chimeric monoclonal antibody that targets mesothelin, a tumor differentiation antigen overexpressed in pancreatic cancer, ovarian cancer, mesothelioma, and other malignancies. We conducted a phase I clinical trial of MORAb-009 in patients with advanced mesothelin-expressing cancers to determine its safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). ...

متن کامل

Biographical Sketch: Nathaniel Allison, 1876–1932

This biographical sketch of Nathaniel Allison corresponds to the historic text, The Classic: Symposium on Arthroplasty: Arthroplasty: Experimental and Clinical Methods, available at DOI 10.1007/s11999-009-1120-3 .

متن کامل

Sir William Arbuthnot Lane, 1856–1943

This biographical sketch on William Arbuthnot Lane corresponds to the historic text, The Classic: The Operative Treatment of Fractures, available at DOI 10.1007/s11999-009-0860-4 .

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2004